New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 14, 2013
10:55 EDTNBS, NBS, ONVO, ONVO, LIFE, LIFE, GSK, GSK, CELG, CELG, BAX, BAX, STEM, STEM, OSIR, OSIR, BLUE, BLUE, SGMO, SGMO, FCSC, FCSC, PSTI, PSTI, MBLTY, MBLTY, ATHX, ATHX, BTX, BTXAlliance for Regenerative Medicine to hold a meeting
2013 Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 14-16 with webcasted presentations to begin on October 14 at 11 am; not all presentations may be webcasted. Webcast Link
News For NBS;ATHX;MBLTY;PSTI;FCSC;SGMO;BLUE;OSIR;STEM;BAX;CELG;GSK;LIFE;ONVO;BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 23, 2015
07:22 EDTBLUESunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 20, 2015
16:03 EDTCELGOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTCELGActive equity options trading on open
Subscribe for More Information
07:23 EDTGSKAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTGSK, BAXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
05:27 EDTCELGCelgene Revlimid approved by EC
Subscribe for More Information
February 19, 2015
18:25 EDTSGMO, BAXPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
12:50 EDTPSTIPluristem says NIH study of PLX-R18 statistically significant
Pluristem Therapeutics announced the results of a recently completed trial conducted by the U.S. National Institutes of Health to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster. Injection of PLX-R18 cells into muscle, as compared to a placebo, resulted in a statistically significant improvement in the recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation, the company said. It added, "The data also suggested that the treatment may potentially be able to shorten time to recovery."
11:19 EDTBTXBioTime management to meet with Jefferies
Subscribe for More Information
08:23 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
07:12 EDTBLUEWharton Health Care Club to hold a conference
Subscribe for More Information
February 18, 2015
16:00 EDTCELGOptions Update; February 18, 2015
Subscribe for More Information
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTCELGCelgene reports FDA expands indication for Revlimid combo
Subscribe for More Information
09:37 EDTCELGOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
09:10 EDTPSTIOn The Fly: Pre-market Movers
Subscribe for More Information
06:47 EDTCELGCelgene initiated with a Buy at Canaccord
Target $156.
05:17 EDTPSTIPluristem Therapeutics reports 'significant' findings in NIH trial of PLX-R18
Pluristem Therapeutics announced the positive results of a recently completed trial conducted by the U.S. National Institutes of Health, or NIH, to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster. Injection of PLX-R18 cells into muscle, as compared to a placebo, resulted in a statistically significant improvement in the recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation. The data also suggested that the treatment may potentially be able to shorten time to recovery. High levels of radiation can destroy the body's ability to produce these three blood lineages, and rapidly regaining that capacity is a key factor in surviving the hematologic component of acute radiation syndrome, or ARS, a condition caused by high-dose irradiation that can involve severe, sometimes lethal damage to the bone marrow as well as other physiologic systems and organs. The objective of this latest trial was to investigate the mechanism of action behind the significant improvement in survival in irradiated mice treated with PLX-R18 that was demonstrated in the NIH's first efficacy study. The results of the current study indicate that intramuscular administration exerts a systemic healing effect on bone marrow, lending further support to the concept that Pluristem's cells work systemically via secretion of therapeutic proteins, although the cells themselves remain in the muscle into which they were initially injected. While additional animal trials are needed prior to FDA approval of PLX-R18 for use in ARS, no human trials would be required because product development is conducted under the FDA's Animal Rule.
February 17, 2015
08:47 EDTBTXBioTime provides update on Cell Cure's product development, partnering
BioTime (BTX) and its subsidiary Cell Cure Neurosciences provided an update on Cell Cure’s product development and partnering activities. On February 16, Cell Cure opened the clinical trial of OpRegen titled “Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy” at Hadassah University Medical Center in Jerusalem, Israel. Patient enrollment is expected to begin shortly. OpRegen consists of animal product-free retinal pigment epithelial cells with high purity and potency. On October 31, 2014, the FDA cleared Cell Cure's Investigational New Drug application to initiate the clinical trial of OpRegen in patients with the severe form of age-related macular degeneration with geographic atrophy.The Phase I/IIa clinical trial, will evaluate three different dose regimens of OpRegen. Following transplantation, the patients will be followed for 12 months at specified intervals, to evaluate the safety and tolerability of the product. Following the initial 12 month period, patients will continue to be monitored at longer intervals for an additional period of time. A secondary objective of the clinical trial will be to examine the ability of transplanted OpRegen to engraft, survive, and moderate disease progression in the patients. In addition to thorough characterization of visual function, a battery of ophthalmic imaging modalities will be used to quantify structural changes and rate of GA expansion. Cell Cure also announced that the option granted to Teva (TEVA) under a Research and Exclusive Option Agreement of October 7, 2010 to license-in rights to its OpRegen product has expired without having been exercised by Teva. Cell Cure will therefore be continuing the clinical development of OpRegen on its own and pursuing discussions with other potential strategic partners, including those that have already indicated interest in participating in development and commercialization of the product. Cell Cure also announced that US patent No. 8,956,866 relating to a proprietary method of manufacturing RPE cells is expected to issue on February 17. This patent combined with other patents and patent applications in the BioTime family of companies provides significant patent protection for this novel therapeutic modality for AMD.
07:38 EDTGSKGlaxo replaces head of struggling U.S. drug unit, Bloomberg reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use